ClinicalTrials.gg
CompletedNCT04876534TOGOUpdated Oct 23, 2026

Tocilizumab in Active Moderate-severe Graves' Orbitopathy

A Phase 2 interventional study of Tocilizumab 20 Mg/mL Intravenous Solution and MethylPREDNISolone Injectable Solution in Graves Ophthalmopathy, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Completed at 4 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2019, registered May 2021).
Updated Oct 23, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Graves Ophthalmopathy with a site in Italy — 3 open to participants now, 7 under way, 3 of them phase 3. Graves Ophthalmopathy · Italy.

Enrollment
17th of 20
56 · median 89
Started
2019
with 1 other
Phase 2
6 of 24
1 open now
Registered
11th of 24
by date
Lead sponsor
2 of 24
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Among the 24 studies in Graves Ophthalmopathy with a site in Italy, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 in phase 2, and was the 11th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

3 of the 24 studies in Graves Ophthalmopathy with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Graves Ophthalmopathy with a site in Italy, or all of them as a file.
02

Study summary

To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and reactivation of disease (Primary Objective) Effect of therapy on disease progression, improvement of QoL, the degree of residual disease after the inflammatory phase and safety of treatment (Secondary Objective)

Read the detailed description

1 Primary Endpoint:

1. Proportion of patients with CAS reduction of 3 points or disease inactivation (CAS\<4) at 12 and 24 weeks

1.2 Secondary Endpoints:

  1. Proportion of patients improved at 24 weeks as assessed by the EUGOGO composite ophthalmic score (see below paragraph#5)
  2. Improvement of quality of life according to the GO-QoL questionnaire at 12 and 24 weeks.
  3. Safety of tocilizumab therapy in patients with GO compared to Methylprednisolone, evaluated on the basis of the following endpoints: Incidence and severity of adverse events, with severity determined according to NCI CTCAE v5.0,
  4. Changes of serum TSH receptor binding and stimulating antibodies, anti-TPO antibodies and serum concentrations of IL-6 and sIL-6 receptor at 12, 24 and 36 and 48weeks of follow up.
  5. Proportion of patients with disease reactivation (CAS > or =4) during follow-up at 24-48 weeks.
  6. Quantification of signs of residual motility abnormalities by motility tests and orbital imaging
  7. Number of rehabilitative surgical interventions at the end of follow-up

2.Study Design and Methods

Randomized, single blind (ophthalmologist), controlled study, IIb phase. The study will be conducted in 5 National centres dedicated to the management of Graves' orbitopathy

The present study will randomize GO patients, euthyroid for at least 6-8 weeks, to two treatments:

  1. Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
  2. Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks

The enrollment period is approximately 24 months

3.Phases of the study

  • Screening phase (-4/-2 to 0 weeks): involves 1 to 2 visits
  • Treatment phase (0 to 12 weeks): assessments at baseline and every 4 weeks
  • Observation phase (12 to 24 weeks): assessments every 6 weeks
  • Follow up (24 to 48 weeks): assessments every 12 weeks

Data from week 24 are used to determine primary and secondary endpoints

4.Definition of improvement, worsening or no change of the secondary end point criteria*

  1. Improvement, when at least two of the following outcome measures improve in one eye, without deterioration in any of the measure in either eyes: a) reduction in palpebral aperture by at least 3 mm; b) reduction in any of the class 2 signs of NOSPECS by at least 2 grades; c) reduction of proptosis by at least 2 mm; d) improvement of ≥8 degrees in any duction or in diplopia (Gorman score); e) improvement in CAS by at least 2 points
  2. Worsening, when optic neuropathy or two of the following occur: a) increase in palpebral aperture by at least 3 mm; b) increase in any of the class 2 signs of NOSPECS by at least 2 grades; c) increase of proptosis by at least 2 mm; d) deterioration of ≥8 degrees in any duction or in diplopia (Gorman score); e) worsening in CAS.
  3. No change, when there are no changes or changes smaller than the above defined parameters

5. Study population

5.1 Withdrawal Rules

  1. Should patients become affected with any of the conditions outlined as exclusion criteria during the study period or follow-up, they will be withdrawn from the study
  2. Should patients require administration of any of the medications listed in the exclusion criteria, according to prohibited medication rules, they will be withdrawn from the study.
  3. Other reasons for study withdrawal are:

    1. refusal of continuing the study medication after having commenced it.
    2. diagnosis of major cardiovascular diseases or neoplasia once treatment has started.
  4. If patients present with a severe complication of GO, i.e. progression to dysthyroid optic neuropathy due to unresponsiveness to treatment, they will be considertreatment failure and will undergo urgent surgical orbital decompression.

Patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the investigator has the right to withdraw a patient from the study at any time. Reasons for withdrawal from the study may include, but are not limited to, the following:

Patient withdrawal of consent

Study termination or site closure

Patient non-compliance, defined as failure to comply with protocol requirements as determined by the investigator or Sponsor

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF. If a patient requests to be withdrawn from the study, this request must be documented in the source documents and signed by the investigator. Patients who withdraw from the study will not be replaced.

5.2 Study Arms

Arm 1: 32 patients with active moderate-severe GO treated with i.v. tocilizumab

Arm 2: 32 patients with active moderate-severe GO treated with i.v. methylprednisolone.

5.3 Study Medications and Dosing Regimen

Tocilizumab, the IMP-test, will be supplied and distribute by Roche packed and labelled.

Upon delivery to the site, site personnel should check for damage and verify proper identity, quantity, integrity of seals and temperature conditions. Site personnel should report any deviations or product complaints to the study monitor upon discovery.

For information on the formulation and handling of tocilizumab see the SmPC and Investigator's Brochure

Methylprednisolone is the IMP-comparator,

For information on the formulation, packaging, and handling of MP, see the SmPC.

Arm 1. Tocilizumab: i.v. infusion of, weight adjusted, 8 mg/kg of TCZ every four weeks (+/- 72 hours) for 12 weeks.

Arm 2. Methylprednisolone (MP): i.v. infusion of 500 mg of MP weekly (+/- 48 hours) for 6 weeks, followed by i.v. infusion of 250 mg of MP one a week (+/- 48 hours) for 6 weeks

5.4 Study duration

Duration of the study: 3 years (2 years for enrollment and one year for follow up)

5.5 Study Discontinuation

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients

Patient enrollment is unsatisfactory

The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.

5.6 Site Discontinuation

The Sponsor has the right to close a site at any time. Reasons for closing a site may include, but are not limited to, the following:

Excessively slow recruitment

Poor protocol adherence

Inaccurate or incomplete data recording

Non-compliance with the International Council for Harmonisation (ICH) guideline for Good Clinical Practice

No study activity (i.e., all patients have completed the study and all obligations have been fulfilled)

6. Statistical considerations and sample size calculation A sample size of 64 patients is planned to provide at least an 80% power if 32 patients per treatment arm were included for an anticipated (improvement) responder rate of 68% in steroid and 95% in tocilizumab treated patients, with a two-tail significance of 0.05.

No patients stratification is planned The calculation is based on the available literature on the significant decrease of the after rituximab and steroid therapy and after tocilizumab and placebo.

64 patients with active GO will be enrolled and an interim analysis of results will be carried out after the first 32 patients (16 in arm 1 and 16 in arm 2) will reach the 24 week endpoint.

All enrolled patients receiving at least one dose of study medication and withdrawing from the study for any reason will be analyzed as non-responder in an ITT population for the 24 weeks primary endpoint.

Statistical Analysis: repeated measures ANOVA and Spearman or Pearson rank test for clinical activity and severity scores; Wilcoxon rank sum test to assess differences between treatment groups; chi-square for response and relapse rates.

An interim analysis of results will be carried out after the first 16 enrolled patients in both arms reach 24 week point), in order to eventually plan for another study perhaps employing s.c. TCZ .

03

Conditions studied

  • Graves Ophthalmopathy

Keywords

  • Graves' orbitopathy
  • Graves' disease
  • Tocilizumab
  • Hyperthyroidism
  • Thyroid's disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Male or female, 18-75 years old
  3. Women of should use effective (abstinence or use contraceptive methods with a failure rate of \<1%) throughout study and for a minimum of 6 months after study drug therapy and must have a negative serum pregnancy test at screening
  4. GO at first diagnosis or at the time of relapse of no more than 9 months' duration.
  5. Patients with moderate-severe active GO (clinical activity score 4/10 assessed at the end of the screening period) untreated or previously treated with i.v. withdrawn for at least 3 months.
  6. Euthyroid for at least 6-8 weeks (serum free hormone concentrations within 20% of normal range), on either anti-thyroid medications (tyonamides) to control hyperthyroidism or L-thyroxine for replacement therapy for hypothyroidism.
  7. Patients will also be allowed to stay on propranolol treatment for the control of tachycardia.

Exclusion criteria

Exclusion Criteria:

  1. Patients with sight-threatening Graves' orbitopathy (severe keratopathy, compression optic neuropathy and inflammatory optic neuropathy).
  2. Treatment with any biological therapy at any time.
  3. Previous oral or intravenous treatment in the last three months except for oral steroid not exceeding a cumulative dose of 1 gr.
  4. Plasmapheresis within 90 days prior to Day 0.
  5. Treatment with intravenous immunoglobulin.
  6. Azathioprine more than 100 mg/day within 30 days before screening.
  7. Administration of given within 30 days prior to administration of (Day 0) or concurrently with tocilizumab (during study).
  8. Splenectomy.
  9. Subjects at risk of bleeding that threatens a vital organ.
  10. History of a major organ transplant or hematopoietic stem cell/marrow transplant.
  11. History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
  12. Required management of infections, as follows: currently on any suppressive therapy for a chronic infection, hospitalization for treatment of infection within 60 days before Day 0, use of parenteral antibiotics within 60 days before Day 0, use of oral antibiotics within 30 days before Day 0.
  13. Pregnancy.
  14. Patients with not willing to use an effective method of throughout study and for a minimum of 6 months after study drug therapy
  15. Breast feeding.
  16. Previous history of intestinal ulceration or diverticulitis or diverticular disease.
  17. Known unstable coronary artery disease.
  18. Significant cardiac arrhythmias.
  19. Severe congestive heart failure.
  20. Other serious chronic illness (including nervous system disease, pulmonary disease including obstructive pulmonary disease, renal disease).
  21. Active infection.
  22. History of recurrent infection or recurrent bacterial infections.
  23. History of sarcoidosis.
  24. Primary or secondary immunodeficiency.
  25. History of IgE-mediated or non-IgE-mediated .
  26. Positive PPD or quantiferon without documentation of treatment for TB infection.
  27. Denied consent to testing.
  28. Previous orbital radiotherapy
  29. positive test.
  30. HBcAb positive test, regardless of HBsAb status, will undergo HBV DNA which, if positive, will be excluded.
  31. antibody positive test at screening.
  32. Positive test for Human Immunodeficiency Virus (HIV) antibody at screening or historically.
  33. (AST) and alanine aminotransferase (ALT) greater or equal to 1.5x (ULN).
  34. Alkaline phosphatase and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is\<35%).
  35. Grade 3 / 4 IgG deficiency and IgA deficiency (IgA \< 10mg/dL).
  36. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including a previous anaphylactic reaction to parenteral administration contrast agents, human or murine proteins or monoclonal antibodies.
  37. Major depression.
  38. Evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.
  39. Current drug or alcohol abuse or dependence.
  40. White blood cells \< 3.0 x 109/L (3000/mm3)
  41. (ANC) \< 2.0 x 109/L (2000/ mm3)
  42. Absolute lymphocyte count \< 0.5 x 109/L (500/ mm3)
  43. count \<100 x 109/L
  44. Serum creatinine > 1.4 mg/dl (124 µmol/L) in female patients and > 1.6 mg/dl (141 µmol/L) in male patients
  45. \<85 g/L (8.5 g/dL; 5.3 mmol/L)
  46. Demyelinating disorders
  47. Treatment with Methotrexate
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks

    Drug: Tocilizumab 20 Mg/mL Intravenous Solution

  • Active comparator
    Methylprednisolone

    32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks

    Drug: MethylPREDNISolone Injectable Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Desease inactivation

    Proportion of patients with CAS reduction of 3 points or disease inactivation (CAS\<4) at 12 and 24 weeks

    Time frame: at 12 and 24 weeks

Secondary outcomes

  1. Desease improvement

    Proportion of patients improved at 24 weeks as assessed by the EUGOGO composite ophthalmic score

    Time frame: 24 weeks

  2. Improvement of quality of life

    Improvement of quality of life according to the GO-QoL questionnaire at 12 and 24 weeks. All Go-QoL questions were scored as 'severely limited' (one point), a 'little limited' (two points), or 'not limited at all'(three points). The questions were transformed from 0 to 100 by the following formula: total score= (raw score- 8)/16 x100. Higher is the final score, better is health.

    Time frame: at 12 and 24 weeks

  3. Incident of adverse events in tocilizumab therapy

    Safety of tocilizumab therapy in patients with GO compared to Methylprednisolone, evaluated on the basis of the following endpoints: Incidence and severity of adverse events, with severity determined according to NCI CTCAE v5.0,

    Time frame: from 0 to 12 weeks

  4. Immunological changes

    Changes of serum TSH receptor binding and stimulating antibodies, anti-TPO antibodies and serum concentrations of IL-6 and sIL-6 receptor at 12, 24 and 36 and 48weeks of follow up.

    Time frame: at 12, 24 and 36 and 48weeks of follow up

  5. Desease relapse

    Proportion of patients with CAS reduction of 3 points from baseline CAS or disease inactivation (CAS\<4) at 12 and 24 weeks. The Clinical activated score (CAS) is a parameter to assess eye impairment in patients with GO. The maximum CAS value is 10.

    Time frame: at 24-48 weeks

  6. Residual desease

    Quantification of signs of residual motility abnormalities by motility tests and orbital imaging

    Time frame: at 48 weeks

  7. Rehabilitative therapy

    Number of rehabilitative surgical interventions at the end of follow-up

    Time frame: at 48 weeks

07

Study locations

4 sites
  • Istituto Auxologico Italiano
    Milan, MI 20149, Italy
  • Azienda Ospedaliero, Universitaria Pisana
    Pisa, PI 56126, Italy
  • Azienda Ospedaliera "Sant'Andrea"
    Roma, RM 00189, Italy
  • Mauriziano Umberto I Hospital
    Torino, TO 10128, Italy
08

References and documents

Publications

  • Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2. PubMed 27099835 ↗
  • Campi I, Vannucchi G, Salvi M. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy. Eur J Endocrinol. 2016 Sep;175(3):R117-33. doi: 10.1530/EJE-15-1164. Epub 2016 Mar 31. PubMed 27032693 ↗
  • Salvi M, Campi I. Medical Treatment of Graves' Orbitopathy. Horm Metab Res. 2015 Sep;47(10):779-88. doi: 10.1055/s-0035-1554721. Epub 2015 Sep 11. PubMed 26361263 ↗
  • Campi I, Tosi D, Rossi S, Vannucchi G, Covelli D, Colombo F, Trombetta E, Porretti L, Vicentini L, Cantoni G, Curro N, Beck-Peccoz P, Bulfamante G, Salvi M. B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases. Thyroid. 2015 Sep;25(9):1043-9. doi: 10.1089/thy.2015.0029. Epub 2015 Aug 13. PubMed 26214745 ↗
  • Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. doi: 10.1210/jc.2014-3014. Epub 2014 Dec 15. PubMed 25494967 ↗
  • Salvi M. Immunotherapy for Graves' ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097. PubMed 25105999 ↗
  • Curro N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, Dazzi D, Guastella C, Pignataro L, Beck-Peccoz P, Ratiglia R, Salvi M. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014 May;24(5):897-905. doi: 10.1089/thy.2013.0445. Epub 2014 Mar 6. PubMed 24417307 ↗
  • Vannucchi G, Covelli D, Campi I, Origo D, Curro N, Cirello V, Dazzi D, Beck-Peccoz P, Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2013 Nov 22;170(1):55-61. doi: 10.1530/EJE-13-0611. Print 2014 Jan. PubMed 24128430 ↗
  • Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves' orbitopathy. J Clin Endocrinol Metab. 2013 Nov;98(11):4291-9. doi: 10.1210/jc.2013-1804. Epub 2013 Sep 5. PubMed 24009135 ↗
  • Vannucchi G, Covelli D, Curro N, Dazzi D, Maffini A, Campi I, Bonara P, Guastella C, Pignataro L, Ratiglia R, Beck-Peccoz P, Salvi M. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab. 2012 May;97(5):E755-9. doi: 10.1210/jc.2011-2614. Epub 2012 Mar 7. PubMed 22399512 ↗
  • Salvi M, Vannucchi G, Curro N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012 Jan;130(1):122-4. doi: 10.1001/archopthalmol.2011.1215. No abstract available. PubMed 22232486 ↗
  • Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007 Jan;156(1):33-40. doi: 10.1530/eje.1.02325. PubMed 17218723 ↗
  • Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Curro N, Simonetta S, Bonara P, Persani L, Guastella C, Wall J, Beck-Peccoz P, Salvi M. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x. PubMed 20529087 ↗
  • Salvi M, Vannucchi G, Campi I, Curro N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol. 2009 May;131(2):360-5. doi: 10.1016/j.clim.2008.12.005. Epub 2009 Feb 4. PubMed 19195932 ↗
  • Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev. 2008 Jun;223:284-99. doi: 10.1111/j.1600-065X.2008.00646.x. PubMed 18613843 ↗
  • Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol. 2010 Oct 15;185(8):4570-81. doi: 10.4049/jimmunol.1001708. Epub 2010 Sep 22. PubMed 20861359 ↗
  • Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3. doi: 10.1126/science.285.5425.260. PubMed 10398604 ↗
  • Gilbert JA, Kalled SL, Moorhead J, Hess DM, Rennert P, Li Z, Khan MZ, Banga JP. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology. 2006 Oct;147(10):4561-8. doi: 10.1210/en.2006-0507. Epub 2006 Jun 22. PubMed 16794009 ↗
  • Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab. 1996 Aug;81(8):2976-9. doi: 10.1210/jcem.81.8.8768861. PubMed 8768861 ↗
  • Campi I, Vannucchi GM, Minetti AM, Dazzi D, Avignone S, Covelli D, Curro N, Ratiglia R, Guastella C, Pignataro L, Beck-Peccoz P, Salvi M. A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy. Ophthalmology. 2013 May;120(5):1092-8. doi: 10.1016/j.ophtha.2012.10.041. Epub 2013 Feb 8. PubMed 23399378 ↗
  • Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodriguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espana Gregori E, Sales-Sanz M; Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018 Nov;195:181-190. doi: 10.1016/j.ajo.2018.07.038. Epub 2018 Aug 4. PubMed 30081019 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2019 to primary completion in Sep 2023, 45 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2022 → Sep 2023 and completion Dec 2023 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 6, 2021
StartActual
Dec 18, 2019
Primary completionActual
Sep 30, 2023was Dec 2022
CompletionActual
Mar 18, 2026was Dec 2023
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Istituto Auxologico Italiano · Milan, Italy
Show 1 removed
  • Istituto Auxologico Italiano · Milano, Italy
Oct 23, 2026
Primary completion
Dec 18, 2022→Sep 30, 2023 (actual)
Oct 23, 2026
Study completion
Dec 18, 2023→Mar 18, 2026 (actual)
Oct 23, 2026
Enrollment
64 (estimated)→56 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Istituto Auxologico Italiano · Milan, Italy
    Show 1 removed
    • Istituto Auxologico Italiano · Milano, Italy
    Primary completion Dec 18, 2022→Sep 30, 2023 (now actual)
    Study completion Dec 18, 2023→Mar 18, 2026 (now actual)
    Enrollment 64 (estimated)→56 (actual)
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04876534
Collaborators
Mauriziano Umberto I Hospital, Istituto Auxologico Italiano, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero, Universitaria Pisana
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Dec 18, 2019
Primary completion
Sep 30, 2023
Completion
Mar 18, 2026
Last update
Oct 23, 2026

Study contacts

Mario MS Salvi, MD
principal investigator · Fondazione IRCCS "Cà Granda" Ospedale Maggiore Policlinico

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion